About MedChemComm

A new, peer-reviewed journal publishing medicinal chemistry research, including new studies related to biologically-active chemical or biochemical entities that can act as pharmacological agents with therapeutic potential or relevance. 

MedChemComm will complement the existing RSC Publishing portfolio of bioscience journals, providing authors in the field with a new, dedicated subject-specific publication.

Co-Editor-in-Chief: Dr Anthony Wood, Pfizer, UK
Co-Editor-in-Chief: Professor Greg Verdine, Harvard University, USA

Examples of areas that will be included:

-  Design, synthesis and biological evaluation of novel chemical or biochemical entities leading to new pharmacological agents, probes and/or potential drugs 

-  Computational, biophysical, physicochemical, molecular biological, proteomic studies of ch/bc entities and their interaction within their biological environment

- Pharmacokinetic behaviour, pharmacodynamics, and drug safety and toxicology

- Chemical biology studies that enable drug discovery 

- Chemical modifications of known chemical or biochemical entities that improve pharmacological properties 

Readership

The journal will be suitable for readers from both academia and industry, conducting research in the field of medicinal chemistry, drug discovery, pharmacology and pharmaceutical research. This will include traditional areas of the chemical sciences together with topics at the interface with biology and physics.

Article Types

The journal will publish issues monthly from mid 2010 and will contain a mix of vibrant and concise research and review articles.